DE69828408D1 - Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung - Google Patents

Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung

Info

Publication number
DE69828408D1
DE69828408D1 DE69828408T DE69828408T DE69828408D1 DE 69828408 D1 DE69828408 D1 DE 69828408D1 DE 69828408 T DE69828408 T DE 69828408T DE 69828408 T DE69828408 T DE 69828408T DE 69828408 D1 DE69828408 D1 DE 69828408D1
Authority
DE
Germany
Prior art keywords
kinase
cell cycle
cell
inhibiting
protein tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828408T
Other languages
English (en)
Other versions
DE69828408T2 (de
Inventor
Mark Robert Barvian
William Alexander Denny
Ellen Myra Dobrusin
James Marino Hamby
Howard Daniel Showalter
Andrew Mark Thompson
Roy Thomas Winters
Zhipei Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69828408D1 publication Critical patent/DE69828408D1/de
Application granted granted Critical
Publication of DE69828408T2 publication Critical patent/DE69828408T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69828408T 1997-08-20 1998-08-13 Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung Expired - Lifetime DE69828408T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5674697P 1997-08-20 1997-08-20
US56746P 1997-08-20
PCT/US1998/016848 WO1999009030A1 (en) 1997-08-20 1998-08-13 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation

Publications (2)

Publication Number Publication Date
DE69828408D1 true DE69828408D1 (de) 2005-02-03
DE69828408T2 DE69828408T2 (de) 2005-12-08

Family

ID=22006345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828408T Expired - Lifetime DE69828408T2 (de) 1997-08-20 1998-08-13 Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung

Country Status (13)

Country Link
US (1) US6150359A (de)
EP (1) EP1003745B1 (de)
JP (1) JP4965021B2 (de)
KR (1) KR20010023089A (de)
AT (1) ATE286053T1 (de)
AU (1) AU742999B2 (de)
BR (1) BR9811956B1 (de)
CA (1) CA2291222C (de)
DE (1) DE69828408T2 (de)
ES (1) ES2235353T3 (de)
NZ (1) NZ502704A (de)
WO (1) WO1999009030A1 (de)
ZA (1) ZA987491B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1801112A1 (de) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bizyklische Pyrimidine und bizyklische 3,4-Dihydropyrimidine als Hemmer der Zellvermehrung
ES2310039T3 (es) 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
AU2002251788A1 (en) 2001-01-19 2002-08-12 Smithkline Beecham Corporation Novel compounds and uses thereof
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
NZ527741A (en) * 2001-02-26 2005-02-25 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
CA2492112A1 (en) * 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CN1863774B (zh) * 2003-10-08 2010-12-15 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
EP1699477A2 (de) * 2003-12-11 2006-09-13 Theravance, Inc. Zusammensetzungen zur verwendung bei der behandlung von durch mutierte rezeptor-tyrosinkinase angetriebene zellproliferationserkrankungen
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
JP2009507924A (ja) * 2005-09-14 2009-02-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼ阻害剤としての５−オキソ−５，８−ジヒドロ−ピリド−ピリミジン
CN101535308A (zh) * 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法
EP2117544A4 (de) * 2006-12-19 2010-03-03 Univ Texas Biomarker zur identifizierung der reaktivierung von stat3 nach src-hemmung
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
ES2383331T3 (es) 2008-02-22 2012-06-20 Irm Llc Compuestos heterocíclicos y composiciones como inhibidores de las Cinasas C-KIT y PDGFR INHIBITORS
CN101684119B (zh) * 2008-09-27 2012-11-28 中国科学院上海药物研究所 5,8-二取代-1,6-二氮杂萘-7-羰酰胺类化合物及其制备方法、组合物和用途
EP3399026A1 (de) 2010-06-14 2018-11-07 The Scripps Research Institute Neuprogrammierung von zellen für ein neues zellschicksal
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
UA117347C2 (uk) 2012-06-13 2018-07-25 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014052365A1 (en) * 2012-09-26 2014-04-03 Mannkind Corporation Multiple kinase pathway inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN110382495B (zh) * 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
JP7393808B2 (ja) * 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
AU2019413683A1 (en) * 2018-12-28 2021-08-12 Spv Therapeutics Inc Cyclin-dependent kinase inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
AU2020275304A1 (en) * 2019-05-16 2021-12-16 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20220389009A1 (en) * 2019-10-01 2022-12-08 Goldfinch Bio, Inc. Substituted 1,6-naphthyridine inhibitors of cdk5
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
EP0584222B1 (de) * 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
FR2706898B1 (de) * 1993-06-25 1995-09-08 Union Pharma Scient Appl
EP0790997B1 (de) * 1994-11-14 2000-03-22 Warner-Lambert Company 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Also Published As

Publication number Publication date
EP1003745A1 (de) 2000-05-31
JP4965021B2 (ja) 2012-07-04
ATE286053T1 (de) 2005-01-15
JP2001515078A (ja) 2001-09-18
BR9811956A (pt) 2000-08-15
CA2291222A1 (en) 1999-02-25
DE69828408T2 (de) 2005-12-08
ES2235353T3 (es) 2005-07-01
ZA987491B (en) 1999-04-21
KR20010023089A (ko) 2001-03-26
EP1003745B1 (de) 2004-12-29
AU742999B2 (en) 2002-01-17
BR9811956B1 (pt) 2010-06-01
NZ502704A (en) 2002-06-28
US6150359A (en) 2000-11-21
AU8828998A (en) 1999-03-08
CA2291222C (en) 2004-03-30
WO1999009030A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE296799T1 (de) P38-inhibitoren
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
MY117696A (en) INHIBITORS OF p38
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
GR20010300018T1 (en) INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
PL346840A1 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
TR200103216T2 (tr) Pirimidinon bileşimleri
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
DK0888353T3 (da) N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
PL333429A1 (en) Benzonaphtyridines useful in particular in treating bronchial diseases
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
ATE256673T1 (de) Chirale phenyldihydrofuranone als pde-iv inhibitoren
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.
DE59712297D1 (de) 3-alkylimidazopyridine
GB9723824D0 (en) Cytostatic agents
MY129421A (en) INHIBITORS OF p38

Legal Events

Date Code Title Description
8364 No opposition during term of opposition